All In Biotech

Drug Trial Radar · NCT04738487

Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)

A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,264 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,264

Actual

Start

Apr 7, 2021

Primary completion

Sep 5, 2024

Study completion Jan 27, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 4, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat people with metastatic non-small cell lung cancer (NSCLC) that is PD-L1 positive. * Metastatic means cancer that has spread to other parts of the body. * PD-L1 positive means that PD-L1 is found on the cancer cells. PD-L1 is a protein that can help the cancer hide from the body's immune system. The goal of this study is to learn if people who receive vibostolimab and pembrolizumab live longer overall and without the cancer getting worse than people who receive pembrolizumab alone.

Conditions

  • Lung Neoplasms
  • Non-Small-Cell Lung Carcinoma

Interventions

  • Pembrolizumab/VibostolimabBiological

    Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).

  • PembrolizumabBiological

    Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) in Participants With PD-L1 TPS ≥50%Time frame: Up to ~39 months

Locations

188 sites in 23 countries. Site status is shown where the registry gives one.

  • Boca Raton Regional Hospital ( Site 0004)

    Boca Raton, Florida

  • Illinois Cancer Care ( Site 0026)

    Peoria, Illinois

  • Mercy Research - Cancer and Hematology Center ( Site 0032)

    Springfield, Missouri

  • Mercy Research - David C. Pratt Cancer Center ( Site 0025)

    St Louis, Missouri

  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0022)

    Mineola, New York

  • Memorial Sloan Kettering Cancer Center ( Site 0013)

    New York, New York

  • Fox Chase Cancer Center-Hematology/Oncology ( Site 0030)

    Philadelphia, Pennsylvania

  • Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 0204)

    Rio de Janeiro, Brazil

  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 0200)

    São Paulo, Brazil

  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0207)

    São Paulo, Brazil

  • Hospital São Carlos-Oncocentro Ce ( Site 0208)

    Fortaleza, Ceará, Brazil

  • Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0201)

    Natal, Rio Grande do Norte, Brazil

  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0206)

    Ijuí, Rio Grande do Sul, Brazil

  • Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro de Pesquisa Novos Tratamentos em Cân

    Porto Alegre, Rio Grande do Sul, Brazil

  • CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0209)

    Florianópolis, Santa Catarina, Brazil

  • BC Cancer Victoria-Clinical Trials Unit ( Site 0107)

    Victoria, British Columbia, Canada

  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0104)

    Hamilton, Ontario, Canada

  • Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0102)

    Kingston, Ontario, Canada

  • Lakeridge Health ( Site 0106)

    Oshawa, Ontario, Canada

  • Centre Intégré de Santé et de Services Sociaux (CISSS) de La-Centre intégré de cancérologie de Lava

    Laval, Quebec, Canada

  • Bradford Hill Norte ( Site 0708)

    Antofagasta, Chile

  • James Lind Centro de Investigacion del Cancer ( Site 0711)

    Temuco, Araucania, Chile

  • CIDO SpA-Oncology ( Site 0707)

    Temuco, Araucania, Chile

  • IC La Serena Research ( Site 0710)

    La Serena, Coquimbo Region, Chile

  • Clínica Puerto Montt ( Site 0713)

    Port Montt, Los Lagos Region, Chile

  • Oncocentro Valdivia ( Site 0715)

    Valdivia, Los Ríos Region, Chile

  • Clinica Universidad Catolica del Maule-Oncology ( Site 0703)

    Talca, Maule Region, Chile

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0712)

    Santiago, Region M. de Santiago, Chile

  • Orlandi Oncologia ( Site 0700)

    Santiago, Region M. de Santiago, Chile

  • FALP ( Site 0702)

    Santiago, Region M. de Santiago, Chile

  • Bradfordhill ( Site 0701)

    Santiago, Region M. de Santiago, Chile

  • The First Affiliated Hospital of Anhui Medical University ( Site 2022)

    Hefei, Anhui, China

  • Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 2017)

    Hefei, Anhui, China

  • Cancer Hospital Chinese Academy of Medical Science-Oncology ( Site 2030)

    Beijing, Beijing Municipality, China

  • Beijing Cancer hospital-intrathoratic deparmtment II ( Site 2001)

    Beijing, Beijing Municipality, China

  • Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2003)

    Beijing, Beijing Municipality, China

  • Beijing Peking Union Medical College Hospital-pneumology department ( Site 2009)

    Beijing, Beijing Municipality, China

  • Beijing Chest Hospital,Capital Medical University ( Site 2020)

    Beijing, Beijing Municipality, China

  • Chongqing Cancer Hospital-Medical Oncology ( Site 2028)

    Chongqing, Chongqing Municipality, China

  • Army Medical Center of People's Liberation Army-respiratory ( Site 2025)

    Chongqing, Chongqing Municipality, China

Showing 40 of 188 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.